| abstract |
The present invention relates to an antagonistic small molecule compound having a Toll-like receptor (TLR) 3/7/9 inhibitory function, and more particularly, toll-like receptor 3/7/9 signaling pathway inhibition. It relates to a novel small molecule compound comprising the same, and to a composition for preventing or treating autoimmune or inflammatory diseases comprising the same. The novel compound according to the present invention blocks the secretion of TNF-α induced by Poly I:C (TLR3 agonist), Imiquimod (TLR7 agonist) or ODN2395 (TLR9 agonist), as well as the production of inflammatory cytokines In particular, it is useful for the prevention or treatment of TLR3/7/9 related autoimmune diseases and inflammatory diseases, including systemic lupus erythematosus and psoriasis. |